Diversified Trust Co. Has $5.75 Million Stock Position in Gilead Sciences, Inc. $GILD

Diversified Trust Co. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,870 shares of the biopharmaceutical company’s stock after buying an additional 3,641 shares during the quarter. Diversified Trust Co.’s holdings in Gilead Sciences were worth $5,753,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in GILD. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences during the third quarter worth $26,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the 2nd quarter worth $30,000. MTM Investment Management LLC increased its holdings in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares in the last quarter. Kilter Group LLC bought a new position in Gilead Sciences during the 2nd quarter worth about $33,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at about $37,000. Institutional investors own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition adds OM336 (gamgertamig), a BCMAxCD3 T‑cell engager designed for rapid, deep B‑cell depletion—strengthens Gilead’s inflammation/autoimmune pipeline and provides a near‑term clinical asset that could drive future revenue if successful. Gilead Sciences to Acquire Ouro Medicines (Business Wire)
• Positive Sentiment: Major media and wire coverage confirms deal size and strategic rationale, increasing market confidence around the transaction’s credibility and near‑term impact. Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion (WSJ) Gilead to buy biotech firm Ouro Medicines in over $2 billion deal (Reuters)
• Positive Sentiment: Analyst support: Bank of America maintained a Buy rating and $162 price target, citing HIV franchise momentum and product upside—analyst backing can bolster investor sentiment. Buy Rating on Gilead (TipRanks / BofA)
• Neutral Sentiment: Health care sector strength is supporting stocks broadly, providing incidental tailwinds to GILD alongside the M&A news. Gilead nears up to $2bn deal for autoimmune biotech (Yahoo Finance)
• Neutral Sentiment: Reported March short‑interest data appear anomalous (showing zero/share changes and NaN), suggesting no clear short‑position signal from the data release. No reliable market pressure evident from short interest.
• Negative Sentiment: Deal and clinical risk: the price (up to $2.18B) is material and the asset is clinical‑stage—clinical trial failure, integration costs, or disappointments on OM336’s commercial potential could weigh on the stock. Gilead nearing up to $2 billion buyout of Ouro Medicines (Reuters)

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GILD. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Barclays began coverage on Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Mizuho upped their price target on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Finally, Morgan Stanley raised their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $157.62.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $137.34 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a market cap of $170.50 billion, a P/E ratio of 20.29, a P/E/G ratio of 1.80 and a beta of 0.36. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The stock’s 50-day simple moving average is $142.98 and its 200 day simple moving average is $128.15.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is currently 48.45%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the insider owned 131,779 shares of the company’s stock, valued at approximately $19,006,485.17. This represents a 2.23% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 309,280 shares of company stock worth $44,068,850. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.